Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Drug

Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal

Fineline Cube Jan 22, 2026
Company Deals

Eyebright Medical to Acquire Control of Delta Medical in $143 M Sports‑Medicine Deal

Fineline Cube Jan 22, 2026
Company Deals

Insilico Licenses NLRP3 Inhibitor ISM8969 to Hengtai in $64M CNS Drug Deal

Fineline Cube Jan 20, 2026
Company Deals

Shionogi Boosts ViiV Stake to 21.7% in $2.1 Billion Deal, Doubles Down on HIV Focus

Fineline Cube Jan 20, 2026
Company Deals Medical Device

EasyDiagnosis Bio to Acquire 51% of Ailex Medical in $5.1M Deal, Gains IVD Platform

Fineline Cube Jan 20, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Deals Drug

Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal

Fineline Cube Jan 22, 2026
Company Drug

Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors

Fineline Cube Jan 22, 2026
Company Drug

Henlius Biotech Initiates US Commercial Supply of Hanquyou, Biosimilar to Herceptin

Fineline Cube Dec 2, 2024

Shanghai Henlius Biotech, Inc. (HKG: 2696) has announced the initiation of commercial supply of its...

Company Drug

ImmuneOnco Biopharmaceuticals Receives NMPA Approval for Lupus Nephritis Phase II Study

Fineline Cube Dec 2, 2024

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG: 1541), a China-based biopharmaceutical company, has announced receiving approval from...

Company Drug

Healthgen Biotechnology’s Plant-Made Albumin Breakthrough: A Milestone in Serum Therapy

Fineline Cube Dec 1, 2024

On November 30th, Healthgen Biotechnology Corp. announced a significant research outcome at the 9th Pharmaceutical...

Company

Shanghai Cell Therapy Group’s Second Attempt at HK IPO Receives Green Light from CICC and CCB International

Fineline Cube Dec 1, 2024

Shanghai Cell Therapy Group Co., Ltd., a leading player in China’s cellular medical health sector,...

Company

Nanjing Leads Biolabs Commences IPO Process with Focus on Innovative Therapies

Fineline Cube Nov 30, 2024

Nanjing Leads Biolabs Co., Ltd., a clinical-stage biopharmaceutical company focused on developing innovative therapies for...

Company Drug

XellSmart Bio-Pharmaceutical Achieves Milestone with First Patient Enrollment in Global iPSC Clinical Study for ALS

Fineline Cube Nov 30, 2024

XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd., in collaboration with Shanghai East Hospital (Tongji University Affiliated East...

Company Drug

Cutia Therapeutic’s CU-20401 Shows Positive Results in Phase II Subcutaneous Fat Reduction Study

Fineline Cube Nov 29, 2024

China-based dermatology specialist Cutia Therapeutic (HKG: 2487) has revealed a positive readout from its Phase...

Company Deals

OBiO Technology Partners with Hanxin Biotechnology to Advance LNP Delivery System

Fineline Cube Nov 29, 2024

China-based gene therapy Contract Research Organization (CRO) OBiO Technology (Shanghai) Co., Ltd (SHA: 688238) has...

Company Medical Device

NMPA Approves Shenzhen Mindray’s Innovative Dual-Mode Ultrasound Diagnostic System

Fineline Cube Nov 29, 2024

The National Medical Products Administration (NMPA) has granted approval to Shenzhen Mindray Bio-Medical Electronics Co.,...

Company Medical Device

NMPA Approves Hangzhou Ruidi Biotechnology’s Steep Pulse Therapy Equipment for Tumor Treatment

Fineline Cube Nov 29, 2024

China’s National Medical Products Administration (NMPA) has granted approval to Hangzhou Ruidi Biotechnology Co., Ltd...

Company Drug

CDE Expands Care Plan with Approvals for Ractigen’s RAG-17 and Vitalgen’s VGR-R01

Fineline Cube Nov 29, 2024

In a swift succession of actions, China’s Center for Drug Evaluation (CDE) has added two...

Policy / Regulatory

NMPA Drafts Medical Representative Management Measures, Seeks Public Input

Fineline Cube Nov 29, 2024

The National Medical Products Administration (NMPA) has released the “Medical Representative Management Measures (draft proposal)”,...

Company Deals

Daiichi Sankyo Invests RMB 1.1 Billion in New ADC Manufacturing Plant in Shanghai

Fineline Cube Nov 29, 2024

Japanese pharmaceutical company Daiichi Sankyo (TYO: 4568) is significantly increasing its investment in China with...

Company Drug

Jiangsu Kanion Pharmaceutical Gets NMPA Clearance for Oncolytic Virus Product KYS202003A

Fineline Cube Nov 29, 2024

Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557) has announced that it has received clinical clearance...

Company Deals

Lingyi Biotechnology and Jolly Pharmaceutical Ink Comprehensive Collaboration Agreement

Fineline Cube Nov 29, 2024

China-based gene therapy specialist Lingyi Biotechnology Co., Ltd has entered into a comprehensive collaboration agreement...

Company Drug

Sichuan Biokin Pharmaceutical’s BL-M08D1 ADC Receives NMPA Approval for Clinical Trials

Fineline Cube Nov 29, 2024

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a China-based pharmaceutical company, has announced that it...

Company Deals

Huadong Medicine Receives FDA Clearance for HDM1005 Clinical Study in Obstructive Sleep Apnea

Fineline Cube Nov 29, 2024

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received clearance from...

Company Drug

Laekna, Inc. Initiates IND-Enabling Study for Monoclonal Antibody LAE123 in Severe Diseases

Fineline Cube Nov 29, 2024

Sino-US biotech company Laekna, Inc. (HKG: 2105) has announced the initiation of an Investigational New...

Company Deals

CORXEL Partners with Apeloa Pharmaceutical for CDMO Services Expansion

Fineline Cube Nov 29, 2024

China-based contract development and manufacturing organization (CDMO) Apeloa Pharmaceutical Co., Ltd (SHE: 000739) has announced...

Company Deals

Wuhan Union Hospital to Transfer Hereditary Thrombophilia Detection Patent to Kingmed Diagnostics

Fineline Cube Nov 29, 2024

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, also recognized as Wuhan...

Posts pagination

1 … 202 203 204 … 612

Recent updates

  • Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal
  • Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors
  • Biokin’s Iza-bren ADC Receives NMPA Filing Acceptance for ESCC, World’s First EGFR×HER3 Bispecific
  • Kawin Technology Withdraws Hepatitis B Filing for Peginterferon Alfacon‑2 After NMPA Feedback
  • Eyebright Medical to Acquire Control of Delta Medical in $143 M Sports‑Medicine Deal
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals Drug

Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal

Company Drug

Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors

Company Drug

Biokin’s Iza-bren ADC Receives NMPA Filing Acceptance for ESCC, World’s First EGFR×HER3 Bispecific

Company Drug

Kawin Technology Withdraws Hepatitis B Filing for Peginterferon Alfacon‑2 After NMPA Feedback

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.